MAIA Biotechnology Announces Establishment of Rule 10b5-1 Trading Plan
22 Novembre 2022 - 2:00PM
Business Wire
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the
“Company”), a targeted therapy, immuno-oncology company focused on
developing potential first-in-class oncology drugs, announced today
that certain officers and directors of the Company, including
Founder and Chief Executive Officer Vlad Vitoc, M.D., and leading
investor and Board Member Stan Smith, Ph.D., plan to initiate
additional investing in the Company’s common stock. These
investments will be entered into as pre-arranged trading plans in
accordance with Rule 10b5-1 of the Securities Exchange Act of 1934,
as amended. The Rule 10b5-1 trading plans will permit the insiders
to purchase shares of the Company’s common stock over a specific
period of time, at times that these insiders might otherwise be
precluded from doing so under insider trading laws or other trading
restrictions, such as the Company’s insider trading policy. The
Rule 10b5-1 trading plans will be administered by an independent
broker. The amount, timing and prices of the purchases will vary
based on market conditions and other factors, as well as being
subject to the present parameters set forth in the plans.
"As MAIA's founder and largest shareholder, I believe that
MAIA's current valuation does not fully reflect our strong business
potential or our vision for long-term growth," said Dr. Vitoc.
“MAIA Biotech’s assets and capabilities are some of the most
innovative in the industry today, and our highly experienced
management team continues to transform the industry. With our
telomere targeting assets, MAIA is very well positioned in the
oncology market.”
“As a major shareholder and director, I have been enthusiastic
about MAIA since the beginning,” said Dr. Smith. “We are developing
a revolutionary approach that has the potential to solve one of the
great challenges plaguing humankind. Management continues to
successfully steer the development of the drug candidates and of
the company. I believe in the Company’s short and long-term
prospects. This is why I have invested in every one of the MAIA
offerings to date. And I plan to continue to invest significant
sums to support the continued progress.”
About MAIA Biotechnology, Inc. MAIA is a targeted
therapy, immuno-oncology company focused on the development and
commercialization of potential first-in-class drugs with novel
mechanisms of action that are intended to meaningfully improve and
extend the lives of people with cancer. Our lead program is THIO, a
potential first-in-class cancer telomere targeting agent in
clinical development for the treatment of NSCLC patients with
telomerase-positive cancer cells. For more information, please
visit www.maiabiotech.com.
Forward Looking Statements MAIA cautions that all
statements, other than statements of historical facts, contained in
this press release, are forward-looking statements. Forward-looking
statements are subject to known and unknown risks, uncertainties,
and other factors that may cause our or our industry’s actual
results, levels or activity, performance or achievements to be
materially different from those anticipated by such statements. The
use of words such as “may,” “might,” “will,” “should,” “could,”
“expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,”
“intend,” “future,” “potential,” or “continue,” and other similar
expressions are intended to identify forward looking statements.
However, the absence of these words does not mean that statements
are not forward-looking. For example, all statements we make
regarding (i) the initiation, timing, cost, progress and results of
our preclinical and clinical studies and our research and
development programs, (ii) our ability to advance product
candidates into, and successfully complete, clinical studies, (iii)
the timing or likelihood of regulatory filings and approvals, (iv)
our ability to develop, manufacture and commercialize our product
candidates and to improve the manufacturing process, (v) the rate
and degree of market acceptance of our product candidates, (vi) the
size and growth potential of the markets for our product candidates
and our ability to serve those markets, and (vii) our expectations
regarding our ability to obtain and maintain intellectual property
protection for our product candidates, are forward looking. All
forward-looking statements are based on current estimates,
assumptions and expectations by our management that, although we
believe to be reasonable, are inherently uncertain. Any
forward-looking statement expressing an expectation or belief as to
future events is expressed in good faith and believed to be
reasonable at the time such forward-looking statement is made.
However, these statements are not guarantees of future events and
are subject to risks and uncertainties and other factors beyond our
control that may cause actual results to differ materially from
those expressed in any forward-looking statement. Any
forward-looking statement speaks only as of the date on which it
was made. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by law.
In this release, unless the context requires otherwise, “MAIA,”
“Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc.
and its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221122005041/en/
MAIA Biotechnology Joseph McGuire Chief Financial Officer
jmcguire@maiabiotech.com 904-228-2603
ICR Westwicke Stephanie Carrington
Stephanie.Carrington@westwicke.com 646-277-1282
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024